AstraZeneca Vaccine Keeps European Regulator Confidence | Corona Virus

This is what the agency’s director general, Emyr Koc, said on Tuesday after several European countries decided to suspend its use due to concerns related to blood clots.

And I recalled that a panel of experts from the European regulator is currently studying cases of reasonable or potential side effects, and its conclusion will be announced on Thursday.

Its role is to determine whether the reported cases of blood clots in a small number of people who have just been vaccinated with the AstraZeneca vaccine are A coincidence or a real side effect.

Ms Cook was not prepared to specifically ask countries that have suspended vaccine use to reconsider their decision, but she did not hide the EMA’s view.

We remain firmly convinced that the benefits of the AstraZeneca vaccine in preventing COVID-19, and the associated risks of hospitalization and death, outweigh the risks of these side effects.

Emer Cooke, General Manager of EMA

Until further notice, there is Not proof The vaccines may have caused these blood clotting problems, which have not been documented in the vaccine clinical trials.

EMA Director General Emer Cooke appears on a screen in the European Union’s press room in Brussels.


Clot formation does not appear in the list of possible side effects observed during these tests, which were conducted on tens of thousands of people.

According to Emyr Cook, the number of thromboembolic cases observed so far in the vaccinated population It does not seem to be higher From the general population.

The EMA should nevertheless investigate the situation Seriously To determine whether there is indeed a causal relationship between vaccine administration and the cases of blood clots that have been reported in some countries.

See also  Ukrainian Boeing shot down in Iran | Canada and three other countries denounce Tehran's position

Experts from the World Health Organization are also looking into the safety of this vaccine on Tuesday.

The United Nations agency said on Monday that it is still advocating the use of an AstraZeneca vaccine to prevent COVID-19, such as EMA.

The Anglo-Swedish pharmaceutical group in the midst of the storm maintains its presence There is no evidence of an increased risk A blood clot caused by a vaccine.

Earlier this morning, British Prime Minister Boris Johnson also called the AstraZeneca vaccine as a vaccine. Certainly And the until far away Efficiency in everyday life times.

The United Kingdom is the first country to approve the vaccine, and more than 11 million people have obtained it so far, without reporting any major problems to regulatory authorities.

Austria discontinued a batch of AstraZeneca vaccine on March 8 after a 49-year-old nurse died of a cause Severe blood clotting problemsA few days after the vaccination.

According to Emyr Cook, this batch has since been verified, but no reasonable correlation has been established for this nurse’s condition.

In general, the Director General of the EMA judges Unlikely Admittedly, a certain batch of vaccine is included It cannot be ruled out althoug.

Denmark was the first country to suspend use AstraZeneca Vaccine, March 11th After reports of serious cases of blood clots In vaccinated people.

Norway followed suit the same day. On Monday, the country reported the death of a caregiver under the age of 50 from a brain haemorrhage.

She was hospitalized Thursday, about a week after receiving the AstraZeneca vaccine, without a proven causal link at this point.

See also  After a year of the pandemic, the Vatican is counting red on its reserves

Another caregiver in her thirties died on Friday in Norway, ten days after receiving the same vaccine.

Iceland, Bulgaria, Ireland and the Netherlands, Germany, France, Italy, SpainSlovenia, Portugal and Latvia later decided to suspend the use of this vaccine as a preventive measure.

On Tuesday, Luxembourg, Cyprus and Sweden did the same.

Canada did not follow suit Continues to advocate for AstraZeneca vaccine safety.

Even the National Advisory Committee on Immunization has recommended since Tuesday To be used for all Canadian adults. In the first opinion, it recommended that it not be used by people over the age of 65.

Leave a Reply

Your email address will not be published.